Fulgent Genetics (FLGT) Asset Writedowns and Impairment (2015 - 2026)

Fulgent Genetics has disclosed Asset Writedowns and Impairment across 12 years of filings, most recently posting $2.2 million for Q2 2026.

• In Q2 2026, Asset Writedowns and Impairment fell 71.98% year-over-year to $2.2 million; the TTM figure through Jun 2026 stood at $1.1 million (down 86.44% YoY), while the FY2025 annual figure was $7.6 million, up 542.08% from the prior year.
• Asset Writedowns and Impairment came in at $2.2 million for Q2 2026 at Fulgent Genetics, up from $1.2 million in the prior quarter.
• In the past five years, Asset Writedowns and Impairment ranged from a high of $11.6 million in Q1 2022 to a low of -$11.8 million in Q4 2024.
• Average Asset Writedowns and Impairment over 5 years is $2.4 million, with a median of $2.1 million recorded in 2025.
• Year-over-year, Asset Writedowns and Impairment jumped 990.23% in 2022 and tumbled 2109.73% in 2024.
• Over 5 years, Asset Writedowns and Impairment stood at $7.3 million in 2022, then slumped by 52.7% to $3.5 million in 2023, then sank by 442.02% to -$11.8 million in 2024, then soared by 80.7% to -$2.3 million in 2025, then surged by 196.58% to $2.2 million in 2026.
• Per Business Quant data, the three most recent Asset Writedowns and Impairment figures were $2.2 million in Q2 2026, $1.2 million in Q1 2026, and -$2.3 million in Q4 2025.